medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2022, Number 3

<< Back Next >>

Arch Neurocien 2022; 27 (3)

La leptina y su papel en la neuroendocrinología de la obesidad

Diéguez-Campa CE, Castillo Ledón-Pretellini J, de los Santos-Coyotl JA, Angel-Chávez LI, Flores-Apodaca IA, Pérez-Neri I

Language: Spanish
References: 44
Page: 28-36
PDF size: 272.67 Kb.


ABSTRACT

No abstract.


REFERENCES

  1. Pública INDS. Encuesta Nacional de Salud y Nutrición de MedioCamino 2016. 2021. https://www.gob.mx/salud/documentos/encuesta-nacional-de-salud-y-nutricion-de-medio-camino-2016

  2. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetesin Latin America and the Caribbean. Bull World Health Organ.2003;81:19-27.https://www.gob.mx/salud/documentos/encuesta-nacional-de-salud-y-nutricion-de-medio-camino-2016

  3. Jaimes L, Cabrera-Wrooman A, Vilches A, Guzmán C,Camacho-Arroyo I. Péptidos anorexigénicos y su participaciónen la conducta alimentaria. Revista de Endocrinología yNutrición. 2005;13(2):67-74. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=3966

  4. Myers Jr MG, Leibel RL, Seeley RJ, Schwartz MW. Obesityand leptin resistance: distinguishing cause from effect. TrendsEndocrinol Metab. 2010;21(11):643-51. doi: 10.1016/j.tem.2010.08.002

  5. Gotoda T, Manning BS, Goldstone AP, Imrie H, Evans AL,Strosberg AD, et al. Leptin receptor gene variation and obesity:lack of association in a white British male population. Hum MolGenet. 1997;6:869-76. doi: 10.1093/hmg/6.6.869

  6. Ahima RS. Revisiting leptin’s role in obesity and weight loss. JClin Invest. 2008;118(7):2380-83. doi: 10.1172/JCI36284

  7. North American Association for the Study of Obesity, NationalHeart, Lung, and Blood Institute, National Institutes of Health(U.S.), NHLBI Obesity Education Initiative. The practical guide:identification, evaluation, and treatment of overweight andobesity in adults. Bethesda: National Institutes of Health NationalHeart Lung and Blood Institute NHLBI Obesity Education InitiativeNorth American Association for the Study of Obesity; 2000.

  8. Warren M, Beck S, Rayburn J. The state of obesity 2018: betterpolicies for a healthier America. Washington: Trust for America’sHealth, Robert Wood Johnson Foundation; 2018. tfah.org/report-details/the-state-of-obesity-2018/

  9. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deathsassociated with underweight, overweight, and obesity. Jama.2005;293(15):1861-7. doi: 10.1001/jama.293.15.1861

  10. World Health Organization. Global health observatory data.2016. https://www.who.int/data/gho

  11. Palloni A, Beltrán-Sánchez H, Novak B, Pinto G, Wong R. Adultobesity, disease and longevity in Mexico. Salud Publica Mex.2015;57:s22-s30. doi: 10.21149/spm.v57s1.7586

  12. Zhang Y, Liu J, Yao J, Ji G, Qian L, Wang J, et al. Obesity:pathophysiology and intervention. Nutrients. 2014;6(11):5153-83. https://doi.org/10.3390/nu6115153

  13. Redinger RN. The pathophysiology of obesity and its clinicalmanifestations. Gastroenterol Hepatol (N Y). 2007;3(11):856-63. PMID: 21960798

  14. Björntorp P. Adipose tissue. EJIFCC. 2000;12(3):68-72. PMID:30532681

  15. La Cava A, Matarese G. The weight of leptin in immunity. NatRev Immunol. 2004;4(5):371-9. doi: 10.1038/nri1350

  16. Chehab FF, Lim ME, Lu R. Correction of the sterility defect inhomozygous obese female mice by treatment with the humanrecombinant leptin. Nat Genet. 1996;12(3):318-20.

  17. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, etal. Leptin inhibits bone formation through a hypothalamic relay:a central control of bone mass. Cell. 2000;100(2):197-207.doi: 10.1016/s0092-8674(00)81558-5

  18. Iciek R, Wender-Ozegowska E, Seremak-Mrozikiewicz A,Drews K, Sodowski K, Pietryga M, et al. Leptin gene, leptingene polymorphisms and body weight in pregnant women withdiabetes mellitus typeI. J Physiol Pharmacol. 2008;59(Suppl4):19-31. PMID: 18955751

  19. Peelman F, Zabeau L, Moharana K, Savvides SN, Tavernier J. 20years of leptin: insights into signaling assemblies of the leptinreceptor. J Endocrinol. 2014;223(1):T9-T23. doi: 10.1530/JOE-14-0264

  20. Hileman SM, Tornøe J, Flier JS, Bjørbæk C. Transcellular transportof leptin by the short leptin receptor isoform ObRa in Madin-Darby Canine Kidney cells. Endocrinology. 2000;141(6):1955-61. doi: 10.1210/endo.141.6.7450

  21. Lee G-H, Proenca R, Montez JM, Carroll KM, DarvishzadehJG, Lee JI, et al. Abnormal splicing of the leptin receptorin diabetic mice. Nature. 1996;379(6566):632-5. doi:10.1038/379632a0

  22. Wauman J, De Ceuninck L, Vanderroost N, Lievens S, TavernierJ. RNF41 (Nrdp1) controls type 1 cytokine receptor degradationand ectodomain shedding. J Cell Sci. 2011;124(6):921-32.doi: 10.1242/jcs.078055

  23. Thompson D, Ravussin E, Bennett PH, Bogardus C. Structure andsequence variation at the human leptin receptor gene in leanand obese Pima Indians. Hum Mol Genet. 1997;6(5):675-9.doi: 10.1093/hmg/6.5.675

  24. Zabeau L, Defeau D, Van der Heyden J, Iserentant H,Vandekerckhove J, Tavernier J. Functional analysis of leptinreceptor activation using a Janus kinase/signal transducerand activator of transcription complementation assay. MolEndocrinol. 2004;18(1):150-61. doi: 10.1210/me.2003-0078

  25. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, StephensTW, Nyce MR, et al. Serum immunoreactive-leptin concentrationsin normal-weight and obese humans. N Engl J Med.1996;334(5):292-5. doi: 10.1056/NEJM199602013340503

  26. Yang R, Barouch LA. Leptin signaling and obesity: cardiovascularconsequences. Circ Res. 2007;101(6):545-59. doi: 10.1161/CIRCRESAHA.107.156596

  27. Oswal A, Yeo G. Leptin and the control of body weight: a reviewof its diverse central targets, signaling mechanisms, and rolein the pathogenesis of obesity. Obesity. 2010;18(2):221. doi:10.1038/oby.2009.228

  28. Farooqi IS, Matarese G, Lord GM, Keogh JM, LawrenceE, Agwu C, et al. Beneficial effects of leptin on obesity, Tcell hyporesponsiveness, and neuroendocrine/metabolicdysfunction of human congenital leptin deficiency. J Clin Invest.2002;110(8):1093-103. doi: 10.1172/JCI15693

  29. De Luis DA, JL PC, Duenas A. Leptin and obesity. Minerva Med.2008;100(3):229-36. PMID: 19182739

  30. Hassink SG, Sheslow DV, de Lancey E, Opentanova I, ConsidineRV, Caro JF. Serum leptin in children with obesity: relationship togender and development. Pediatrics. 1996;98(2):201-3.PMID:8692618

  31. Tups A. Physiological models of leptin resistance.J N e u r o e n d o c r i n o l . 2009; 21(11):961- 7 1 . d o i :10.1111/j.1365-2826.2009.01916.x

  32. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptinaction and leptin resistance. Annu Rev Physiol. 2008;70:537-56. doi: 10.1146/annurev.physiol.70.113006.100707

  33. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M,Rizzon P, et al. Plasma leptin is independently associated withthe intima-media thickness of the common carotid artery. Int JObes Relat Metab Disord. 2001;25(6):805-10. doi: 10.1038/sj.ijo.0801623

  34. Poetsch MS, Strano A, Guan K. Role of leptin in cardiovasculardiseases. Front Endocrinol. 2020;11:354. doi: 10.3389/fendo.2020.00354

  35. Fulton S, Décarie-Spain L, Fioramonti X, Guiard B, NakajimaS. The menace of obesity to depression and anxiety prevalence.Trends Endocrinol Metab. 2022;33(1):18-35. doi: 10.1016/j.tem.2021.10.005

  36. de Moura FB, Kohut SJ, Bergman J. Medications developmentfor food-based and drug use disorders. Adv Pharmacol.2019;86:197-236. doi: 10.1016/bs.apha.2019.04.005

  37. Berner LA, Brown TA, Lavender JM, Lopez E, Wierenga CE, KayeWH. Neuroendocrinology of reward in anorexia nervosa andbulimia nervosa: Beyond leptin and ghrelin. Mol Cell Endocrinol.2019;497:110320. doi: 10.1016/j.mce.2018.10.018

  38. Shimizu Y, Son C, Aotani D, Nomura H, Hikida T, Hosoda K, etal. Role of leptin in conditioned place preference to high-fat dietin leptin-deficient ob/ob mice. Neurosci Lett. 2017;640:60-3.doi: 10.1016/j.neulet.2017.01.033

  39. de Assis GG, Murawska-Ciałowicz E. Leptin-A Potential Bridgebetween Fat Metabolism and the Brain’s Vulnerability toNeuropsychiatric Disorders: A Systematic Review. J Clin Med.2021;10(23):5714. doi: 10.3390/jcm10235714

  40. Godfrey N, Borgland SL. Diversity in the lateral hypothalamicinput to the ventral tegmental area. Neuropharmacology.2019;154:4-12. doi: 10.1016/j.neuropharm.2019.05.014

  41. Coccurello R, Maccarrone M. Hedonic Eating and the “DeliciousCircle”: From Lipid-Derived Mediators to Brain Dopamineand Back. Front Neurosci. 2018;12:271. doi: 10.3389/fnins.2018.00271

  42. Zanchi D, Depoorter A, Egloff L, Haller S, Mählmann L, LangUE, et al. The impact of gut hormones on the neural circuit ofappetite and satiety: A systematic review. Neurosci Biobehav Rev.2017;80:457-75. doi: 10.1016/j.neubiorev.2017.06.013

  43. de Clercq NC, Frissen MN, Groen AK, Nieuwdorp M. GutMicrobiota and the Gut-Brain Axis: New Insights in thePathophysiology of Metabolic Syndrome. Psychosom Med.2017;79(8):874-9. doi: 10.1097/PSY.0000000000000495

  44. Das UN. Obesity: genes, brain, gut, and environment. Nutrition.2010;26(5):459-73. doi: 10.1016/j.nut.2009.09.020




2020     |     www.medigraphic.com